Abstract

The sharing of legacy preclinical safety data among pharmaceutical companies and its integration with other information sources offers unprecedented opportunities to improve the early assessment of drug safety. Here, we discuss the experience of the eTOX project, which was established through the Innovative Medicines Initiative to explore this possibility.

  • Subscribe to Nature Reviews Drug Discovery for full access:

    $265

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    et al. A multiscale simulation system for the prediction of drug-induced cardiotoxicity. J. Chem. Inf. Model. 51, 483–492 (2011).

  2. 2.

    et al. Hepatotoxicity prediction by systems biology modeling of disturbed metabolic pathways using gene expression data. ALTEX 34, 219–234 (2017).

  3. 3.

    et al. Management of organic impurities in small molecule medicinal products: deriving safe limits for use in early development. Regul. Toxicol. Pharmacol. 84, 116–123 (2017).

  4. 4.

    et al. Applicability Domain Analysis (ADAN): a robust method for assessing the reliability of drug property predictions. J. Chem. Inf. Model. 54, 1500–1511 (2014).

  5. 5.

    et al. Ensuring confidence in predictions: a scheme to assess the scientific validity of in silico models. Adv. Drug Deliv. Rev. 86, 101–111 (2015).

Download references

Author information

Affiliations

  1. Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra, 08003 Barcelona, Spain.

    • Ferran Sanz
    •  & Manuel Pastor
  2. Novartis Institute for Biomedical Research, Basel, CH-4002, Switzerland.

    • François Pognan
    •  & Philippe Marc
  3. Bayer AG, 13353 Berlin, Germany.

    • Thomas Steger-Hartmann
    •  & Joerg Wichard
  4. Synapse Research Management Partners, 08007 Barcelona, Spain.

    • Carlos Díaz
    •  & Montserrat Cases
  5. Lhasa Ltd, Leeds LS11 5PS, UK

    • Katharine Briggs
    •  & David K. Watson
  6. Molecular Networks GmbH, 90411 Nürnberg, Germany

    • Thomas Kleinöder
    •  & Chihae Yang
  7. Sanofi, 65926 Frankfurt am Main, Germany

    • Alexander Amberg
  8. GlaxoSmithKline Research and Development Ltd, Stevenage SG1 2NY, UK

    • Maria Beaumont
  9. University of Leicester, Leicester LE1 7RH, UK

    • Anthony J. Brookes
  10. Technical University of Denmark (DTU), 2800 Lyngby, Denmark

    • Søren Brunak
  11. Liverpool John Moores University, Liverpool L3 3AF, UK

    • Mark T. D. Cronin
  12. Universität Wien, 1090 Vienna, Austria

    • Gerhard F. Ecker
  13. Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), 30625 Hannover, Germany

    • Sylvia Escher
  14. Pfizer Ltd, Groton, Connecticut 06340, USA. Current affiliation: AstraZeneca, Waltham, Massachusettts 02451, USA

    • Nigel Greene
  15. ESTEVE, 08041 Barcelona, Spain

    • Antonio Guzmán
  16. European Bioinformatics Institute, European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK

    • Anne Hersey
  17. UCB Pharma SA, 1070 Brussels, Belgium

    • Pascale Jacques
  18. Janssen Pharmaceutica NV, 2340 Beerse, Belgium

    • Lieve Lammens
  19. Chemotargets SL, 08003 Barcelona, Spain

    • Jordi Mestres
  20. F. Hoffmann-La Roche AG, CH-4070 Basel, Switzerland

    • Wolfgang Muster
  21. H. Lundbeck A/S, 2500 Copenhagen, Denmark

    • Helle Northeved
  22. AstraZeneca AB, SK10 2NA Cheshire, UK. Current affiliation: Lhasa Ltd, Leeds LS11 5PS, UK

    • Marc Pinches
  23. Universitat Politècnica de València, 46022 València, Spain

    • Javier Saiz
  24. Servier, 45000 Orléans, France

    • Nicolas Sajot
  25. ICREA, 08010 Barcelona, Spain & Barcelona Supercomputing Center (BSC), 08034 Barcelona, Spain

    • Alfonso Valencia
  26. Erasmus Universitair Medisch Centrum, 3015 CE Rotterdam, The Netherlands

    • Johan van der Lei
  27. Vrije Universiteit Amsterdam, 1081 Amsterdam, The Netherlands

    • Nico P. E. Vermeulen
  28. Boehringer Ingelheim International GmbH, 88379 Biberach an der Riss, Germany

    • Esther Vock
  29. Inte:Ligand GmbH, 1070 Vienna, Austria

    • Gerhard Wolber
  30. Lead Molecular Design S.L., 08172 Sant Cugat del Vallès, Spain

    • Ismael Zamora

Consortia

  1. eTOX

Authors

  1. Search for Ferran Sanz in:

  2. Search for François Pognan in:

  3. Search for Thomas Steger-Hartmann in:

  4. Search for Carlos Díaz in:

  5. Search for Montserrat Cases in:

  6. Search for Manuel Pastor in:

  7. Search for Philippe Marc in:

  8. Search for Joerg Wichard in:

  9. Search for Katharine Briggs in:

  10. Search for David K. Watson in:

  11. Search for Thomas Kleinöder in:

  12. Search for Chihae Yang in:

  13. Search for Alexander Amberg in:

  14. Search for Maria Beaumont in:

  15. Search for Anthony J. Brookes in:

  16. Search for Søren Brunak in:

  17. Search for Mark T. D. Cronin in:

  18. Search for Gerhard F. Ecker in:

  19. Search for Sylvia Escher in:

  20. Search for Nigel Greene in:

  21. Search for Antonio Guzmán in:

  22. Search for Anne Hersey in:

  23. Search for Pascale Jacques in:

  24. Search for Lieve Lammens in:

  25. Search for Jordi Mestres in:

  26. Search for Wolfgang Muster in:

  27. Search for Helle Northeved in:

  28. Search for Marc Pinches in:

  29. Search for Javier Saiz in:

  30. Search for Nicolas Sajot in:

  31. Search for Alfonso Valencia in:

  32. Search for Johan van der Lei in:

  33. Search for Nico P. E. Vermeulen in:

  34. Search for Esther Vock in:

  35. Search for Gerhard Wolber in:

  36. Search for Ismael Zamora in:

Competing interests

Some of the authors are employed in the pharmaceutical industry or in small and medium-sized enterprises, as indicated in the author affliations.

Corresponding authors

Correspondence to Ferran Sanz or François Pognan.

Supplementary information

PDF files

  1. 1.

    Supplementary information S1 (box)

    eTOX-related web sites and publications